Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03873688

Enrollment

Registered

2019-03-13

Start date

2019-01-02

Completion date

2019-10-31

Last updated

2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

expiratory muscle training, cough, respiratory muscle strength, exercise capacity

Brief summary

Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by recurrent airway infections, affecting many systems including lung, pancreas and sweat glands. Cough is an important defense mechanism for clearing the secretions that increase in respiratory diseases. There have been studies investigating the effect of expiratory muscle training on disease groups such as chronic obstructive pulmonary disease, multiple sclerosis, parkinson's disease, and the elderly and healthy individuals. Studies that evaluating effects of expiratory muscle training in cystic fibrosis are limited in the literature. The aim of this study was to evaluate the effect of cough strength in children and adolescents with CF and the effect of expiratory muscle training program on cough strength, exercise capacity, respiratory muscle strength and quality of life.

Interventions

OTHERexpiratory muscle training

The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

8 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed with cystic fibrosis * 8-18 years * Clinically stable during last six weeks

Exclusion criteria

* hemoptysis * low saturation (SpO2\<90%) * acute lower respiratory tract infection * cardiac problems (heart failure, arrhythmia, cardiomyopathy, etc.) * cognitive problems * pneumothorax

Design outcomes

Primary

Measure	Time frame	Description
Cough capacity	6 weeks	peak expiratory flow meter

Secondary

Measure	Time frame	Description
Respiratory muscle strength	every two weeks	maximal expiratory pressure, maximal inspiratory pressure
Exercise capacity	6 weeks	six minute walking test

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026